News coverage about Meridian Bioscience (NASDAQ:VIVO) has trended somewhat positive this week, Alpha One reports. The research group, a division of Accern, rates the sentiment of press coverage by reviewing more than 20 million news and blog sources. Alpha One ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Meridian Bioscience earned a media sentiment score of 0.22 on Alpha One’s scale. Alpha One also gave news headlines about the company an impact score of 78 out of 100, meaning that recent press coverage is likely to have an effect on the company’s share price in the next several days.
These are some of the headlines that may have effected Alpha One’s scoring:
- ETFs with exposure to Meridian Bioscience, Inc. : May 19, 2017 (finance.yahoo.com)
- FDA says Billerica firm’s lead tests may be faulty in some cases (finance.yahoo.com)
- UPDATE 3-U.S. health officials warn of problems with Meridian lead tests (finance.yahoo.com)
- Meridian Bioscience, Inc. breached its 50 day moving average in a Bearish Manner : VIVO-US : May 18, 2017 (finance.yahoo.com)
- Meridian Bioscience, Inc. :VIVO-US: Earnings Analysis: Q2, 2017 By the Numbers : May 18, 2017 (finance.yahoo.com)
Shares of Meridian Bioscience (NASDAQ:VIVO) opened at 13.60 on Friday. Meridian Bioscience has a one year low of $10.75 and a one year high of $20.68. The firm has a 50 day moving average of $14.06 and a 200 day moving average of $15.02. The stock has a market cap of $573.95 million, a P/E ratio of 19.18 and a beta of 1.00.
Meridian Bioscience (NASDAQ:VIVO) last announced its quarterly earnings results on Friday, April 28th. The company reported $0.22 EPS for the quarter, beating analysts’ consensus estimates of $0.19 by $0.03. The company had revenue of $54.13 million during the quarter, compared to analysts’ expectations of $51.16 million. Meridian Bioscience had a return on equity of 18.51% and a net margin of 15.13%. Meridian Bioscience’s revenue was up 5.6% on a year-over-year basis. During the same period in the prior year, the business posted $0.24 EPS. On average, equities research analysts predict that Meridian Bioscience will post $0.68 EPS for the current fiscal year.
The business also recently declared a quarterly dividend, which was paid on Thursday, May 18th. Stockholders of record on Monday, May 8th were paid a $0.125 dividend. The ex-dividend date was Thursday, May 4th. This represents a $0.50 dividend on an annualized basis and a dividend yield of 3.68%. Meridian Bioscience’s dividend payout ratio (DPR) is presently 71.43%.
A number of research analysts have recently issued reports on the stock. Piper Jaffray Companies set a $9.00 price target on shares of Meridian Bioscience and gave the stock a “sell” rating in a research note on Wednesday, January 25th. Canaccord Genuity upped their target price on shares of Meridian Bioscience from $13.00 to $15.00 and gave the stock a “hold” rating in a research report on Wednesday, May 3rd. Zacks Investment Research upgraded shares of Meridian Bioscience from a “sell” rating to a “hold” rating in a research report on Saturday, April 29th. CL King initiated coverage on shares of Meridian Bioscience in a research report on Tuesday, March 28th. They set a “neutral” rating on the stock. Finally, Craig Hallum lowered shares of Meridian Bioscience from a “buy” rating to a “hold” rating in a research report on Tuesday, January 31st. One investment analyst has rated the stock with a sell rating, five have assigned a hold rating and one has given a buy rating to the company’s stock. The stock presently has a consensus rating of “Hold” and an average target price of $14.75.
TRADEMARK VIOLATION NOTICE: This news story was originally published by Transcript Daily and is the sole property of of Transcript Daily. If you are reading this news story on another site, it was illegally stolen and reposted in violation of U.S. and international trademark & copyright legislation. The legal version of this news story can be accessed at https://transcriptdaily.com/2017/05/20/somewhat-favorable-news-coverage-likely-to-impact-meridian-bioscience-vivo-stock-price-updated-updated-updated.html.
About Meridian Bioscience
Meridian Bioscience, Inc is a life science company engaged in the development, manufacture, sale and distribution of diagnostic test kits for gastrointestinal, viral, respiratory and parasitic infectious diseases, and elevated blood lead levels, and the manufacture and distribution of bulk antigens, antibodies, polymerase chain reaction (PCR)/quantitative PCR (qPCR) reagents, nucleotides, competent cells and bioresearch reagents used by researchers and other diagnostic manufacturers.
Receive News & Ratings for Meridian Bioscience Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Meridian Bioscience Inc. and related companies with MarketBeat.com's FREE daily email newsletter.